Cargando…
HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition
Effective experimental prophylactic vaccines against viral pathogens such as herpes simplex virus type 1 (HSV-1) have been shown to protect the host through T and/or B lymphocyte-driven responses. Previously, we found a live-attenuated HSV-1 mutant, 0ΔNLS used as a prophylactic vaccine, provided sig...
Autores principales: | Gmyrek, Grzegorz B., Berube, Amanda N., Sjoelund, Virginie H., Carr, Daniel J. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508094/ https://www.ncbi.nlm.nih.gov/pubmed/36151255 http://dx.doi.org/10.1038/s41598-022-20180-0 |
Ejemplares similares
-
An intact complement system dampens cornea inflammation during acute primary HSV-1 infection
por: Filiberti, Adrian, et al.
Publicado: (2021) -
Vaccine-induced Antibodies Target Sequestered Viral Antigens to Prevent Ocular HSV-1 Pathogenesis, Preserve Vision, and Preempt Productive Neuronal Infection
por: Royer, Derek J., et al.
Publicado: (2019) -
The Durability of Vaccine Efficacy against Ocular HSV-1 Infection Using ICP0 Mutants 0∆NLS and 0∆RING Is Lost over Time
por: Carr, Daniel J. J., et al.
Publicado: (2021) -
Loss of Osteopontin Expression Reduces HSV-1-Induced Corneal Opacity
por: Filiberti, Adrian, et al.
Publicado: (2020) -
Tripartite-Motif 21 (TRIM21) Deficiency Results in a Modest Loss of Herpes Simplex Virus (HSV)-1 Surveillance in the Trigeminal Ganglia Following Cornea Infection
por: Berube, Amanda, et al.
Publicado: (2022)